Platform deals gain pace in India's pharma and healthcare sectors
Consolidation in India's pharma and healthcare is picking up as private equity funds and strategic buyers build larger businesses through acquisitions.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
India's pharmaceutical and healthcare sectors are entering a new wave of consolidation, as private equity funds and strategic buyers increasingly build bigger companies through acquisitions. Moody's, citing Mint, reported this based on comments from Subhakanta Bal, managing director at Rothschild & Co.
Examples include ChrysCapital's July purchase of a 70.68% stake in Novartis India from its parent, and KKR's August agreement to acquire Medicover's Indian hospital business for roughly $1.4 billion. Torrent Pharmaceuticals is acquiring JB Chemicals, and Mankind Pharma is buying BSV.
Bal expects dealmaking to continue in branded medicines and healthcare services, while Indian drugmakers increasingly look overseas for assets with lower valuations.
why it matters
For markets, this signals steady domestic growth in the sector, which Bal says is relatively insulated from geopolitical uncertainty. The story is sector-specific and does not change the broader market picture.
tags
instruments
sources
- Platform deals on the rise in pharma and healthcare: Rothschild & Co. MD Subhakanta Bal — Moody's, 25 October 2026 at 05:03 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗